- Home
- TDUP vs SLS Comparison
TDUP vs SLS Comparison
Compare TDUP & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | SLS |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 750.9M | 706.7M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TDUP | SLS |
|---|---|---|
| Price | $3.41 | $5.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.50 | $7.00 |
| AVG Volume (30 Days) | 2.6M | ★ 6.2M |
| Earning Date | 03-02-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.36 | 62.69 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $310,813,000.00 | N/A |
| Revenue This Year | $13.06 | N/A |
| Revenue Next Year | $10.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.53 | N/A |
| 52 Week Low | $2.29 | $0.95 |
| 52 Week High | $12.28 | $6.14 |
Technical Indicators
Market Signals| Indicator | TDUP | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 54.96 |
| Support Level | N/A | $1.48 |
| Resistance Level | $5.27 | $6.14 |
| Average True Range (ATR) | 0.34 | 0.50 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 5.33 | 37.99 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.